Moclobemide versus fluoxetine for a major depressive episode |
| |
Authors: | C. Reynaert P. Janne M. Parent J. Mirel L. Hazzen |
| |
Affiliation: | (1) University Department of Psychiatry, Clinical University of Mont-Godinne, Avenue G. Therasse 1, B-5530 Mont (Yvoir), Belgium;(2) Psychiatric Hospital, Henri-Chapelle, Belgium;(3) Psychogeriatric Hospital, Montigny, Belgium;(4) N.V. Roche S.A., Brussels, Belgium |
| |
Abstract: | The efficacy and tolerability of moclobemide (300–600 mg daily) and fluoxetine (20–40 mg daily) were compared in a 6-week, double-blind study of 65 inpatients and 34 outpatients suffering from major depressive episodes (DSM III-R). No statistically significant differences between the two treatment groups were noted regarding efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs). Moclobemide (300–600 mg daily) and fluoxetine (20–40 mg daily) would thus appear to be comparable both in antidepressant efficacy and tolerability. Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not. Sexual dysfunction was reported in two patients taking fluoxetine. |
| |
Keywords: | Moclobemide Fluoxetine Major depressive episode Antidepressant drug Dosage Sexual dysfunction |
本文献已被 SpringerLink 等数据库收录! |
|